It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Thank you.
Some features of ATS will be disabled while you continue to use an ad-blocker.
Originally posted by AllinTheMind89
Someone in an earlier post said something about how this monetary thing is coming to an end. Not to sound sadistic or anything, but I'd rather everything in this country go straight to hell, and have this whole plan backfire on the pharmaceutical companies and the government. Let it get REALLY out of hand because I'd rather that happen then have millions of "uneducated" and unknowing Americans, become slaves to our country's leaders.
The overall goal of BioShield and BioShield II combined is to energize a biodefense sector that will provide the medicines the nation needs.
By building a market for bioterrorism medical countermeasures, this law, like the Lieberman-Hatch legislation, will provide an incentive for companies to risk their capital in developing countermeasures critical to America’s homeland security.
"Now preparing for bioterrorism is good for business and good for our national security."
Also this morning, in comments to the Infectious Disease Society of America (IDSA), Lieberman emphasized the synergy between research on medicines for a bioterror attack and IDSA’s agenda of research on new antibiotics to counter antibiotic resistance. IDSA issued a major report today – Bad Bugs, No Drugs – that endorses the type of incentives that Senators Lieberman and Hatch have proposed.
The Working Group recommends the President’s request provide $870 million in no-year funding that was requested, but not yet funded, by the previous Administration in FY 2008 for expanding cell and egg-based vaccine capacity, purchasing antivirals for the federal stockpile, and accelerating research and development of rapid diagnostic tests that can be
used to enable doctors and field epidemiologists to quickly evaluate patients for influenza
viruses.
Sincerely, 3-V Biosciences, Inc. American College of Occupational and Environmental Medicine American Lung Association American Osteopathic Association American Public Health Association American Red Cross Association for Professionals in Infection Control and Epidemiology (APIC) Association of Public Health Laboratories Association of State and Territorial Health Officials Breathe Technologies Campaign for Public Health Center for Biosecurity, UPMC Center for Infectious Disease Research and Policy GlaxoSmithKline HX Diagnostics, Inc. Infectious Diseases Society of America Juvaris BioTherapeutics, Inc. National Association of County and City Health Officials Novavax RetireSafe Trust for America’s Health United American Nurses, AFL-CIO VaxInnate Xcellerex
"To be very direct, the effect that the money was not included (in stimulus bill 2008) did not really impact the building a capacity for the vaccine manufacturers that have been recipients of funding in the previous two years to basically develop excess capacity. The money which is in the order of several hundred million dollars was REALLY for advanced development of new generation flu vaccines as well as antiviral drugs. So it did delay what I would say, maybe, moving forward on that front, but did not impact the capacity-building that was paid for already.
Just to highlight one thing though, and here's just a little nuance, that's maybe not a LITTLE nuance. When we were planning for the H5N1 potential pandemic, it was believed that you needed two immunizations of a pandemic flu strain to confer immunity. Given that H5N1 would be an entirely different virus that's circulating in the human population, since you would be starting from really having no basis for immunity in the human population whether it be the United States or the world. That may be a very different consideration for this particular virus, and it may be too early to say whether you would need one or two, but clearly I think, just highlight, there is much more that we need to glean from as to the particular virus we're confronting, this H1N1, uh swine flu virus, and how it relates to the innate human immunity that exists now and what would be necessary to confer enough immunity to protect the population."
Preserving Gains from Public Health Emergency Preparedness Cooperative Agreements
Jennifer B. Nuzzo, Michael Mair, Crystal Franco
Biosecurity and Bioterrorism: Biodefense Strategy, Practice, and Science. March 2009, 7(1): 35-36.
These and other important gains are threatened by the current trend to cut federal support for preparedness activities. As states continue to struggle financially, they will be less able to meet the increasing requirements of federal public health preparedness programs.
Recommendations
Congress and HHS should reverse the trend of cuts to funding of the Public Health Cooperative Agreements. A rollback of federal funding and declines in state budgets threaten to reverse critical improvements in state and local public health preparedness. Despite increases in federal requirements for emergency preparedness, annual federal grant support for preparedness planning has decreased significantly significantly since 2005. The Center for Biosecurity estimates that federal support for public health preparedness decreased by 20% between FY2005 and FY2008. At the same time, state and local governments are facing drastic shortfalls in their own budgets that will limit their ability to support preparedness programs. Following sizeable cuts in federal public health preparedness funds in 2006, states reported having to reduce staff time spent on preparedness and delay completion of preparedness plans and training staff. According to the Association of State and Territorial Health Officials (ASTHO), 27% of states have eliminated entire public health programs and a minimum of one-third of all states will lay off or cut staff in FY2009. These reductions in federal and state funding for public health emergency programs, combined with the overall economic downturn, jeopardize the many substantial and hard-won gains in readiness that the past 8 years of investment and planning have produced.
Originally posted by Crakeur
Originally posted by Truth4hire
* The "Pandemic" will most likely be used to initiate forced vaccinations with TamiFlu
There's a problem with this theory.
Oseltamivir (TamiFlu) helps alleviate symptoms of the flu, it is not a vaccine. It can be taken when you have come in contact with an infected person and it will lessen the symptoms and that is it.
It cannot be taken to prevent catching the disease and, again, it is not a vaccine.
Originally posted by Truth4hire
The amount of money and manhours being spent says they are pretty sure this pandemic is on its way. How can they be so sure? A vaccine can't be developed until its known what strain or variation to make the vaccine for.
"To date, all tested viruses are resistant to amantadine and rimantadine but are susceptible to oseltamivir and zanamivir. The purpose of this report is to provide detailed information on the drug susceptibility of the newly detected S-OIVs, which will aid in making recommendations for treatment and prophylaxis for swine influenza A (H1N1) infection."